Table 4. Subgroup Analysis of the Associations between HT and Clinicopathological Features of Papillary Thyroid Cancer by Study Location.
Variable | Asia | Non-Asia | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | Europe | America | ||||||||||
No. of studies | No. of HT/non-HT | OR (95% CI) | No. of studies | No. of HT/non-HT | OR (95% CI) | No. of studies | No. of HT/non-HT | OR (95% CI) | No. of tudies | No. of HT/non-HT | OR (95% CI) | |
ETE | 26 | 6,266/19,912 | 0.75 (0.70–0.80) | 12 | 1,045/2,615 | 0.75 (0.62–0.89) | 5 | 302/1,036 | 0.74 (0.54–1.02) | 7 | 743/1,579 | 0.75 (0.51–1.05) |
Multifocality | 25 | 6,374/19,289 | 1.19 (1.05–1.34) | 17 | 1,755/3,681 | 1.20 (0.95–1.53) | 9 | 953/2,398 | 1.09 (0.78–1.51) | 8 | 802/1,283 | 1.36 (0.95–1.95) |
LN metastasis | 35 | 7,576/23,949 | 0.81 (0.71–0.93) | 22 | 2,191/5,429 | 0.88 (0.62–1.25) | 11 | 1,172/3,613 | 1.10 (0.59–2.06) | 11 | 1,019/1,816 | 0.68 (0.50–0.93) |
Distant metastasis | 3 | 261/2,173 | 0.63 (0.19–2.01) | 5 | 696/2,048 | 0.47 (0.30–0.76) | 3 | 578/1,639 | 0.53 (0.32–0.87) | 2 | 118/409 | 0.19 (0.03–1.06) |
Recurrence | 14 | 2,365/9,996 | 0.55 (0.43–0.70) | 5 | 474/995 | 0.39 (0.27–0.57) | 3 | 350/864 | 0.37 (0.23–0.59) | 2 | 124/131 | 0.43 (0.22–0.85) |
HT, Hashimoto thyroiditis; OR, odds ratio; CI, confidence interval; ETE, extrathyroidal extension; LN, lymph node.